Tibet Haisco Pharmaceutical Co. Ltd.

Primary objective: To compare the pharmacokinetic characteristics of HSK39297 tablets in subjects with normal hepatic function and subjects with severe hepatic impairment; Secondary objective: To evaluate the safety of HSK39297 tablets in subjects with normal hepatic function and subjects with severe hepatic impairment; Exploratory objective: To evaluate the pharmacodynamic characteristics of HSK39297 tablets in subjects with normal hepatic function and subjects with severe hepatic impairment.

Primary objective: To evaluate the long-term safety of HSK39297 tablets in patients with primary IgA nephropathy. Secondary objective: To evaluate the long-term efficacy of HSK39297 tablets in patients with primary IgA nephropathy.

Primary Objective: To evaluate the safety and tolerability of HSK45030 dispersible tablets in healthy volunteers. Secondary Objectives: 1. To evaluate the pharmacokinetic (PK) characteristics of HSK45030 dispersible tablets in healthy volunteers. 2. To evaluate the effect of food on the pharmacokinetics of HSK45030 dispersible tablets. 3. To evaluate the effects of different routes of administration on the pharmacokinetics of HSK45030. Exploratory Objectives: 1. To preliminarily investigate the metabolites and major excretion pathways of HSK45030 in humans, and to investigate the cumulative excretion rates of unchanged HSK45030 and metabolites (if applicable) in urine and feces. 2. To preliminarily evaluate the effect of HSK45030 on the QT interval. 3. To preliminarily evaluate the palatability of HSK45030 dispersible tablets.